全文获取类型
收费全文 | 1368742篇 |
免费 | 95708篇 |
国内免费 | 3012篇 |
专业分类
耳鼻咽喉 | 20113篇 |
儿科学 | 42138篇 |
妇产科学 | 39308篇 |
基础医学 | 191278篇 |
口腔科学 | 40583篇 |
临床医学 | 114941篇 |
内科学 | 268946篇 |
皮肤病学 | 30958篇 |
神经病学 | 108104篇 |
特种医学 | 54380篇 |
外国民族医学 | 435篇 |
外科学 | 212671篇 |
综合类 | 32252篇 |
现状与发展 | 6篇 |
一般理论 | 451篇 |
预防医学 | 93956篇 |
眼科学 | 32786篇 |
药学 | 103279篇 |
4篇 | |
中国医学 | 3251篇 |
肿瘤学 | 77622篇 |
出版年
2018年 | 12711篇 |
2016年 | 11474篇 |
2015年 | 12791篇 |
2014年 | 17934篇 |
2013年 | 26868篇 |
2012年 | 35244篇 |
2011年 | 37155篇 |
2010年 | 22030篇 |
2009年 | 21372篇 |
2008年 | 35206篇 |
2007年 | 38280篇 |
2006年 | 38829篇 |
2005年 | 37260篇 |
2004年 | 36357篇 |
2003年 | 35147篇 |
2002年 | 34520篇 |
2001年 | 64294篇 |
2000年 | 66060篇 |
1999年 | 55994篇 |
1998年 | 14924篇 |
1997年 | 13641篇 |
1996年 | 13141篇 |
1995年 | 12401篇 |
1994年 | 11607篇 |
1992年 | 43184篇 |
1991年 | 41619篇 |
1990年 | 40917篇 |
1989年 | 39882篇 |
1988年 | 37270篇 |
1987年 | 36715篇 |
1986年 | 35203篇 |
1985年 | 33379篇 |
1984年 | 25046篇 |
1983年 | 21242篇 |
1982年 | 12776篇 |
1981年 | 11649篇 |
1979年 | 24110篇 |
1978年 | 17199篇 |
1977年 | 14990篇 |
1976年 | 13501篇 |
1975年 | 15402篇 |
1974年 | 18225篇 |
1973年 | 17695篇 |
1972年 | 16942篇 |
1971年 | 15855篇 |
1970年 | 15007篇 |
1969年 | 14445篇 |
1968年 | 13528篇 |
1967年 | 12095篇 |
1966年 | 11318篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
Improvement in Tricuspid Annular Plane Systolic Excursion with Pulmonary Hypertension Therapy in Pediatric Patients 下载免费PDF全文
4.
5.
Koel Dutt P N Agarwal Rajdeep Singh Vikas Singh Tomar 《The Indian journal of surgery》2015,77(1):62-64
Haemophilia is a common cause of genetically inherited bleeding disorders. Pseudotumours occur in 1–2 % of persons with severe forms of haemophilia. These are a result of repeated haemorrhage into soft tissues, subperiosteum or a site of bone fracture with inadequate resorption of the extravasated blood. There are a number of therapeutic alternatives for this dangerous condition: surgical removal, percutaneous management, irradiation, embolization etc. In this case report, we describe the natural history, clinical course and successful surgical management of a patient with haemophilia who presented with a massive pseudotumour. We also briefly review the relevant literature on the various therapeutic modalities that have been implemented in the management of this rare complication. Though surgeons may be averse to operate on haemophiliacs, primary surgical management as done in our case may prove to be the definitive treatment option for such patients. 相似文献
6.
7.
8.
9.
10.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献